Apetrei Laboratory

Our laboratory uses nonhuman primate models and a multidisciplinary approach including virology, immunology and epidemiology to understand HIV pathogenesis and design new strategies for infection control.

Assessment of SIV diversity and pathogenesis in natural hosts. Understanding SIV diversity is a very important issue of AIDS research, as both HIV-1 and HIV-2 have a simian origin and some consider that there is a significant risk that new SIVs may emerge as human pathogens in the future. Through multiple collaborations, we discovered and characterized new SIVs naturally infecting mandrills (SIVmnd-2), red-eared guenons (SIVery), agile mangabey (SIVagi), black colobus (SIVsat), Preuss’s monkey (SIVpre) and Bioko drill (SIVdrl). The use of these new viruses (mainly originating from an island that separated from mainland Africa 12,000 years ago), provided new information that was instrumental in recalibrating the molecular clocks and tracking back in time the origins of SIVs in natural hosts. We performed a second recalibration of the molecular trees by comparing the SIVver diversity on the two sides of the Drakensberg Mountains in South Africa. These studies allowed harmonizing the molecular clocks with the pathogenic features of SIV infection in natural hosts, thus demonstrating that SIVs emerged millions of years ago.

Our lab is heavily involved in studies on the pathogenesis of SIV infection in natural hosts. Over the last two decades, our work in African green monkeys, mandrills and sooty mangabeys changed some of the core paradigms of AIDS research and essentially contributed to the emergence of the current view in which immune activation of T cells is the main factor behind disease progression in HIV-infected patients. We developed numerous animal models for these studies and opened numerous avenues in the field of the pathogenesis of SIV infection in natural hosts. We are the only group that combines the study of SIV diversity with that of SIV pathogenesis; we performed the only studies of SIV pathogenesis in wild animals, and identified an animal model for exposed-uninfected individuals. Key publications related to this work:

  • Worobey M, Telfer P, Souquière S, Hunter M, Coleman CA, Metzger MJ, Reed P, Makuwa M, Hearn G, Honarvar S, Roques P, Apetrei C, Kazanji M, & Marx PA. Island biogeography reveals the deep history of SIV. Science 2010; 329: 1487.
  • Ma D, Jasinska A, Kristoff J, Grobler JP, Turner T, Jung Y, Schmitt C, Raehtz K, Feyertag F, Martinez Sosa N, Wijewardana V, Burke DS, Robertson DL, Tracy R, Pandrea I, Freimer N, & Apetrei C for “The International Vervet Research Consortium”: SIVagm infection in wild African green monkeys from South Africa: Epidemiology, natural history and evolutionary considerations. Plos Pathogens 2013; 10: e1003011.
  • Ma D, Jasinska A, Feyertag F, Wijewardana V, Kristoff J, He T, Raehtz KD, Schmitt C, Antonio M, Tracy R, Turner T, Robertson DL, Pandrea I, Freimer N, Apetrei C, for The International Vervet Research Consortium: Factors associated with SIV transmission in a natural African nonhuman primate host in the wild. Virol. 2014; 88: 5687-5705.
  • Apetrei C, Gaufin T, Gautam R, Vinton C, Hirsch VM, Lewis M, Brenchley JM, & Pandrea I. Pattern of SIVagm infection in patas monkeys suggests that host adaptation to SIV infection may result in resistance to infection and virus extinction. J Infect Dis 2010; 201: S371-S376.
  • Apetrei C, Sumpter B, Souquiere S, Chahroudi A, Makuwa M, Reed P, Pandrea I, Roques P, & Silvestri G. Immunovirological analyses of chronically SIVmnd-1- and SIVmnd-2-infected mandrills (Mandrillus sphinx). J Virol 2011; 85: 13077-13087.

Improvement of SIV/Rhesus macaque model of HIV infection. We discovered a large array of new SIVsmm strains (SIVsmm is the virus that is at the origin of the macaque models for AIDS research) that mirrors the diversity of HIV-1 subtypes. During these studies we found the origin of SIVmac in sooty mangabeys and we showed that the emergence of this reference strain might have accidentally occurred during kuru research in the 1960-1970s’. We completed an ambitious program of improving the currently available animal model for AIDS research by developing viral strains that reproduce HIV diversity and that more closely reproduce the pathogenesis of HIV-1 in rhesus macaques. The currently available SIV strains for use in macaques have a very limited genetic diversity and, being generated through multiple in vitro and in vivo passages, they are too pathogenic. This may prevent identification of the correlates of immune protection. We compared and contrasted the evolution of SIVs in sooty mangabeys and macaques and we developed multiple transmitted founder (TF) infectious molecular clones (IMCs) of the newly identified SIVsmm strains representative each major lineage. We characterized the in vivo pathogenicity of both the SIVsmm swarms and that of the TF IMCs in rhesus macaques. We tested in vivo multiple new TF simian-human immunodeficiency viruses.

  • Apetrei C, Kaur A, Lerche NW, Metzger M, Pandrea I, Hardcastle J, Fakelstein S, Bohm R, Koehler J, Traina-Dorge V, Williams T, Staprans S, Plauche G, Veazey RS, McClure H, Lackner AA, Gormus B, Robertson DL & Marx PA. Molecular epidemiology of SIVsm in U.S. Primate Centers unravels the origin of SIVmac and SIVsm. J Virol 2005, 79: 8991-9005.
  • Apetrei C, Lerche N, Pandrea I, Gormus B, Silvestri G, Kaur A, Robertson DL, Hardcastle J, Lackner A & Marx P: Kuru experiments triggered the emergence of pathogenic SIVmac. AIDS 2006, 21: 317-321.
  • Gautam R, Carter AC, Katz N, Butler IF, Barnes M, Hasegawa A, Ratterree M, Silvestri G, Marx PA, Hirsch VM, Pandrea I & Apetrei C. In vitro characterization of primary SIVsmm isolates belonging to different lineages. In vitro growth on rhesus macaque cells is not predictive for in vivo replication in rhesus macaques. Virology, 2007; 362: 257-270.
  • Fischer W, Apetrei C, Santiago ML, Li Y, Gautam R, Pandrea I, Shaw GM, Hahn BH, Letvin N, Nabel G, & Korber BT: Evolution of diversity in HIV-1 and SIVsmm genomes: Implications for vaccine challenge studies. J Virol 2012; 86: 13217-13231.
  • Li H, Wang S, Kong R, Ding W, Lee F-H, Parker Z, Learn GH, Kim E, Hahn P, Policicchio B, Brocca Cofano E, Dleage C, Hao X-P, Chuang G-Y, Gorman J, Lewis MG, Hatzioannou T, Santra S, Apetrei C, Pandrea I, Alam SM, Liao H-X, Tomaras GD, Montefiori DC, Farzan M, Chertova EN, Bess JW, Keele BF, Estes JD, Lifson JD, Doms RW, BF Haynes, Sodroski JG, Kwong PD, Hahn BH, Shaw GM: Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. 2016. Proc Natl Acad Sci USA 2016; 113:E3413-E3422.

 

HIV/SIV-induced mucosal dysfunction and HIV-associated comorbidities. In the era of ART, the clinical presentation of the disease is shifting. Accelerated aging, as well as non-SIV comorbidities are the current key features of HIV infection in patients on ART. In general, these pathologies are due to the residual immune activation and inflammation in patients receiving ART. Considering these aspects and the fact that the new therapeutic approaches should target these new clinical aspects of infection, we developed a model for the study of comorbidities and we showed a direct relation between hypercoagulability and microbial translocation, immune activation and inflammation. We are using the SIVsab-infected pigtailed macaque which more faithfully recapitulates the features of HIV infection (i.e., hypercoagulability, persistent inflammation and cardiovascular disease) than the SIVmac-infected rhesus macaques, in which these pathologies are inconsistent. We are actively investigating strategies aimed at controlling microbial translocation, mucosal immune activation and inflammation or hypercoagulation. The goal is to identify therapeutic regimens that can be associated to ART to help HIV-infected patients to control the sources of systemic immune activation which is responsible of accelerated aging and comorbidities. Most of these studies are either submitted or in progress.

  • Pandrea I, Cornell E, Wilson C, Ribeiro R, Ma D, Kristoff J, Xu C, Haret-Richter GS, Trichel A, Apetrei C, Landay A, Tracy R: Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood 2012; 120: 1357-1366.
  • Hao XP, Lucero CM, Turkbey B, Bernardo ML, Morcock DL, Deleage C, Trubey CM, Smedley J, Klatt NR, Giavedoni LD, Del Prete GQ, Keele BF, Rao SS, Gregory Alvord L, Choyke PL, Lifson JD, Brenchley JM, Apetrei C, Pandrea I, & Estes JD: Experimental colitis in SIV-uninfected rhesus macaques recapitulates the microbial translocation and systemic immune activation of SIV infection. Nature Communications 2015; 6: 8020.
  • Pandrea I, Xu C, Stock JL, Frank DN, Ma D, Policicchio BB, He T, Kristoff J, Cornell E, Haret-Richter GS, Trichel A, Ribeiro RM, Tracy R, Wilson C, Landay A, & Apetrei C: Combination antibiotic and antiinflammatory therapy reduces acute inflammation and hypercoagulation in SIV-infected pigtailed macaques. Plos Pathogens 2016; 12; e1005384.
  • Kristoff J, Haret-Richter GS, Ma D, Ribeiro RM, Xu C, Cornell E, Stock JL, He T, Mobley AD, Trichel A, Wilson C, Tracy R, Landay A, Apetrei C, Pandrea I: Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. J Clin Invest. 2014; 24: 2802-2806.
  • Sivanandham R, Brocca-Cofano E, Krampe N, Falwell E, Apetrei C, Pandrea I: Neutrophil extracellular trap (NET) production in SIV-infected nonhuman primates. J Clin Invest. 2018; 128: 5178-5183.

 

Cure research. We developed an animal model of spontaneous controlled SIV infection by infecting RMs with SIVsab. We showed that complete control (<1 copy/ml) occurs in 100% of RMs and that the controlled virus is replication competent, as it can be reactivated by both CD8+ cell depletion and administration of latency reversing inhibitors (LRAs), and also can be transmitted to uninfected macaques. We are testing LRAs in this model. We developed a second model for cure research, namely a post-treatment controller model (similar to the Visconti patients). This model was generated by using one of the new SIVsmm strains and prolonged (>9 months) administration of conventional antiretroviral therapy. We used this model to test LRA romidepsin and demonstrated that HDACi can reactivate latent virus in vivo. We are exploring Treg depletion as a new cure strategy in which through a single intervention we can boost immune responses while improving viral reactivation. We explore the role of diet on the size and the distribution of the SIV reservoir. For our cure research program, we optimized multiple virological methods for quantifying the virus in vivo and in vitro (single copy assays, 2LTR circles, vDNA and cell-associated vRNA quantification in tissues).

  • He T, Brocca-Cofano E, Policicchio BB, Gautam R, Stock JL, Mandell D, Raehtz KD, Xu C, Pandrea I & Apetrei C: Cutting Edge. T regulatory cell depletion reactivates SIV in controller macaques while boosting SIV-specific T lymphocytes. J. Immunol. 2016; 197: 4535-4539. PMC-in progress
  • Policicchio BB, Xu C, Brocca-Cofano E, Raehtz KD, He T, Ma D, Li H, Sivanandhan R, […], Ribeiro RM, Pandrea I, & Apetrei C: Multi-dose romidepsin reactivates latent, replication competent SIV in postantiretroviral rhesus macaque controllers. Plos Pathogens, 2016; 12: e1005879. PMC5025140
  • Pandrea I, Gaufin T, Gautam R, Kristoff J, Mandell D, Montefiori DL, Keele BF, Ribeiro RM, Veazey RS & Apetrei C. Functional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4+ T cells and is reverted by CD8+ cell depletion. Plos Pathogens 2011; 7: e1002170. PMC3150280 Comment in Nature Medicine: Alison Farell: Infection: Modeling the elite. Nat Med 2011; 17: 1058
  • Ma D, Xu C, Cillo A, Policicchio BB, Kristoff J, Haret-Richter G, Mellors JW, Pandrea I, & Apetrei C: SIVsab infection of rhesus macaques as a model of complete immunological suppression with persistent reservoirs of replication-competent virus: Implications for cure research. J. Virol 2015; 89: 6155-6160. PMC4442440.
  • Policiccio BB, Pandrea I, & Apetrei C: Animal models for HIV cure research. Front Immunol 2016, eCollection 2016. PMC4729870

He T, Xu C, Frank D, Stock JL, Haret-Richter GS, Dunsmore T, Krampe N, Martin KJ, Policicchio BB, Raehtz KD, Wilson C, Landay AL, Ribeiro RM, Apetrei C, Pandrea I: The effects of fat diet in progressive vs nonprogressive models of SIV infection. J Clin Invest. 2019; 129; in press.

Division of Infectious Diseases
Academic Administrative Office

818 Scaife Hall
3550 Terrace Street
Pittsburgh, PA 15261
412-383-7963

Center for Care of Infectious Diseases

Falk Medical Building
3601 Fifth Avenue
Pittsburgh, PA 15213
Patient Appointments: 412-647-7228